Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MBX BiosciencesMBX +0.03%14 Cash-to-Debt is 125.29 as of Jun. 2026, which is 80% below its 10-year median of 627.02. GuruFocus rates MBX with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, MBX Biosciences ranks better than 77.99% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MBX Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 125.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MBX Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for MBX Biosciences's Cash-to-Debt or its related term are showing as below:
MBX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 92.11 Med: 627.02 Max: 1852.2
Current: 125.29
During the past 4 years, MBX Biosciences's highest Cash to Debt Ratio was 1852.20. The lowest was 92.11. And the median was 627.02.
MBX's Cash-to-Debt is ranked better than 77.99% of 1395
companies
in the Biotechnology industry
Industry Median: 7.17
vs MBX: 125.29
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
MBX Biosciences Cash-to-Debt Related Terms
MBX Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for MBX Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, MBX Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MBX Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MBX Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where MBX Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBX Biosciences (MBX) has a Cash-to-Debt of 125.29 as of Jun. 2026. This is 80% below median its historical median of 627.02. Over the past decade, MBX Biosciences' Cash-to-Debt has ranged from 92.11 to 1,852.20. According to the industry distribution chart, MBX Biosciences ranks #307 out of 1395 companies in the Biotechnology industry, placing it in the top 22%.
Is MBX Biosciences' Cash-to-Debt too high?
MBX Biosciences' current Cash-to-Debt of 125.29 is 80% below median its 10-year median of 627.02. Over the past 10 years, this metric has ranged from a low of 92.11 to a high of 1,852.20. The Biotechnology industry median Cash-to-Debt is 7.17. MBX Biosciences' value of 125.29 is 1647.4% above this industry median. Based on the distribution chart, MBX Biosciences ranks #307 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MBX Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Cash-to-Debt compare to BEAM and CLDX?
According to the Biotechnology industry distribution chart, MBX Biosciences ranks #307 out of 1395 companies for Cash-to-Debt. This places MBX Biosciences in the top 22% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.17. MBX Biosciences' value of 125.29 is 1647.4% above this benchmark. Historically, MBX Biosciences' own Cash-to-Debt has ranged from 92.11 to 1,852.20 over the past decade. While the company's 10-year median is 627.02 vs. the industry median of 7.17, MBX Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MBX Biosciences's current Cash-to-Debt of 125.29 is 1647.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MBX Biosciences's current Cash-to-Debt is 125.29, which is 80% below median its own 10-year median of 627.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Cash-to-Debt of 125.29. The current Cash-to-Debt is 125.29, which is 80% below median its 10-year median of 627.02 and 1647.4% above the Biotechnology industry median of 7.17. MBX Biosciences' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Cash-to-Debt is 125.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
14GF Score
Get the complete analysis for MBX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBX has been successfully added to your 
